The Speciality Medicines IPO GMP is attracting attention among investors as the SME IPO opens for subscription on March 20, 2026. With growing interest in pharmaceutical and healthcare-related companies, tracking its grey market premium (GMP), price band, and listing expectations is essential.
In this guide by Finowings, we provide detailed insights on the IPO, including latest GMP trends, investment requirements, subscription details, and expert analysis.
Speciality Medicines IPO Details
The Speciality Medicines IPO is a book-built issue of ₹29.14 crores, consisting entirely of a fresh issue of 0.24 crore shares. This makes it a straightforward offering aimed at raising growth capital for the company.
IPO Type: Fresh issue
Total Issue Size: ₹29.14 crores
Number of Shares: 0.24 crore
This IPO will be listed on the BSE SME platform, providing opportunities for retail and HNI investors.
Important Dates
IPO Opening Date: March 20, 2026
IPO Closing Date: March 24, 2026
Allotment Date: March 25, 2026
Tentative Listing Date: March 30, 2026
Exchange: BSE SME
Speciality Medicines IPO Price Band & Lot Size
Price Band: ₹117 – ₹124 per share
Lot Size: 1,000 shares
💸 Investment Requirement
Retail Investor Minimum: ₹2,48,000 (2 lots / 2,000 shares)
HNI Minimum: ₹3,72,000 (3 lots / 3,000 shares)
Investors should calculate the investment amount based on the upper price band to ensure sufficient funds are available when applying.
Speciality Medicines IPO GMP (Grey Market Premium)
The Speciality Medicines IPO GMP is a critical factor for investors tracking potential listing gains.
Key Points About GMP
Positive GMP: Indicates strong demand and potential gains at listing
Low/Zero GMP: Suggests neutral market response
Negative GMP: Indicates weak interest
Note: GMP is unofficial and can fluctuate daily based on market sentiment and subscription response.
Subscription and Market Sentiment
The subscription of this SME IPO will influence GMP trends:
Retail investors: Critical for IPO success
HNI category: Adds credibility and demand
Overall market sentiment: Can impact GMP and listing performance
A well-subscribed IPO is more likely to see a positive GMP ahead of the listing date.
Expected Listing Performance
Based on SME IPO trends:
High GMP + strong subscription → Listing above issue price
Moderate subscription → Listing near issue price
Weak subscription → Listing below issue price
Investors should monitor both GMP and subscription updates to make informed decisions.
Pros & Cons of Speciality Medicines IPO
Pros
Presence in the growing pharmaceutical sector
SME IPO with manageable issue size
Potential for healthy listing gains if demand is strong
Cons
High capital requirement for retail investors
SME IPOs can be volatile
Limited public track record
Finowings Expert Opinion
At Finowings, we recommend investors:
Track Speciality Medicines IPO GMP daily
Monitor subscription levels across retail and HNI categories
Avoid making investment decisions solely based on GMP
Smart investors combine fundamental research with market signals for safer investing.
Conclusion
The Speciality Medicines IPO GMP will provide insights into investor sentiment and expected listing performance. Retail and HNI investors should take a balanced approach, considering both GMP and company fundamentals before investing.
Stay updated with Finowings for:
Latest GMP updates
IPO reviews
Listing day strategies
Disclaimer: This content is for informational purposes only. Please consult your financial advisor before investing.
Post a Comment